Binding properties of antagonists to Cannabinoid receptors in intact cells

Fundamental and Clinical Pharmacology

Volumn 25, Issue 2, 2011, Pages 200-210

  Wennerberg, Marie ^a   Cheng, Leifeng ^a   Hjorth, Stephan ^a   Clapham, John C ^b   Balendran, Anudharan ^a   Vauquelin, Georges ^c  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA   (United Kingdom)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Bovine serum albumin; Cannabinoid; CB1 receptor; Intact cells; Radioligand binding; Rebinding; Receptor kinetic

Indexed keywords

AZ 12288553; AZ 12491187; BOVINE SERUM ALBUMIN; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; RADIOLIGAND; RIMONABANT; TARANABANT; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; DRUG BINDING; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

AMIDES; HEK293 CELLS; HUMANS; LIGANDS; PIPERIDINES; PROTEIN BINDING; PYRAZOLES; PYRIDINES; RECEPTOR, CANNABINOID, CB1; SERUM ALBUMIN, BOVINE; SULFONES; TIME FACTORS;

EID: 79952404677     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2010.00843.x     Document Type: Article

References (44)

1. Howlett A.C., Barth F., Bonner T.I. et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. (2002) 54 161-202.
2. Pertwee R.G. The pharmacology of cannabinoid receptors and their ligands: an overview. Int. J. Obes (Lond). (2006) 30(Suppl 1) S13-S18.
3. Herkenham M., Lynn A.B., Little M.D. et al. Cannabinoid receptor localization in brain. Proc. Natl Acad. Sci. USA (1990) 87 1932-1936.
4. Mackie K. Cannabinoid receptors: Where they are and what they do. J. Neuroendocrinol. (2008) 20(Suppl 1) 10-14.
5. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 365 61-65.
6. Onaivi E.S., Ishiguro H., Gong J.P. et al. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann. N Y Acad. Sci. (2006) 1074 514-536.
7. Van Sickle M.D., Duncan M., Kingsley P.J. et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science (2005) 310 329-332.
8. Freund T.F., Katona I., Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. (2003) 83 1017-1066.
9. Piomelli D. The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci. (2003) 4 873-884.
10. Cota D. CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health. Diabetes. Metab. Res. (2007) 23 507-517.
11. Turu G., Simon A., Gyombolai P. et al. The role of diacylglycerol lipase in constitutive and angiotensin AT1 receptor-stimulated cannabinoid CB1 receptor activity. J. Biol. Chem. (2007) 282 7753-7757.
12. Barnett-Norris J., Lynch D., Reggio P.H. Lipids, lipid rafts and caveolae: their importance for GPCR signaling and their centrality to the endocannabinoid system. Life Sci. (2005) 77 1625-1639.
13. Lynch D.L., Reggio P.H. Cannabinoid CB1 receptor recognition of endocannabinoids via the lipid bilayer: molecular dynamics simulations of CB1 transmembrane helix 6 and anandamide in a phospholipid bilayer. J. Comput. Aided Mol. Des. (2006) 20 495-509.
14. Makriyannis A., Tian X., Guo J. How lipophilic cannabinergic ligands reach their receptor sites. Prostaglandins Other Lipid Mediat. (2005) 77 210-218.
15. Tian X., Guo J., Yao F., Yang D.P., Makriyannis A. The conformation, location, and dynamic properties of the endocannabinoid ligand anandamide in a membrane bilayer. J. Biol. Chem. (2005) 280 29788-29795.
16. Kapur A., Hurst D.P., Fleischer D. et al. Mutation studies of Ser7.39 and Ser2.60 in the human CB1 cannabinoid receptor: evidence for a serine-induced bend in CB1 transmembrane helix 7. Mol. Pharmacol. (2007) 71 1512-1524.
17. Price M.R., Baillie G.L., Thomas A. et al. Allosteric modulation of the cannabinoid CB1 receptor. Mol. Pharmacol. (2005) 68 1484-1495.
18. Addy C., Rothenberg P., Li S. et al. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers. J. Clin. Pharmacol. (2008) 48 734-744.
19. Armstrong H.E., Galka A., Lin L.S. et al. Substituted acyclic sulfonamides as human cannabinoid-1 receptor inverse agonists. Bioorg. Med. Chem. Lett. (2007) 17 2184-2187.
20. Despres J.P., Golay A., Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. (2005) 353 2121-2134.
21. Pi-Sunyer F.X., Aronne L.J., Heshmati H.M., Devin J., Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA (2006) 295 761-775.
22. Van Gaal L.F., Rissanen A.M., Scheen A.J., Ziegler O., Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet (2005) 365 1389-1397.
23. Fong T.M., Guan X.M., Marsh D.J. et al. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S, 2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(t rifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents. J. Pharmacol. Exp. Ther. (2007) 321 1013-1022.
24. Rinaldi-Carmona M., Barth F., Heaulme M. et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. (1994) 350 240-244.
25. Rinaldi-Carmona M., Pialot F., Congy C. et al. Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain. Life Sci. (1996) 58 1239-1247.
26. Fierens F.L., Vanderheyden P.M., Roggeman C., Vande Gucht P., De Backer J.P., Vauquelin G. Distinct binding properties of the AT(1) receptor antagonist [(3)H]candesartan to intact cells and membrane preparations. Biochem. Pharmacol. (2002) 63 1273-1279.
27. Hara M., Tozawa F., Itazaki K., Mihara S., Fujimoto M. Endothelin ET(B) receptors show different binding profiles in intact cells and cell membrane preparations. Eur. J. Pharmacol. (1998) 345 339-342.
28. Packeu A., De Backer J.P., Van Liefde I., Vanderheyden P.M., Vauquelin G. Antagonist-radioligand binding to D2L-receptors in intact cells. Biochem. Pharmacol. (2008) 75 2192-2203.
29. Copeland R.A., Pompliano D.L., Meek T.D. Drug-target residence time and its implications for lead optimization. Nat. Rev. Drug. Discov. (2006) 5 730-739.
30. Tummino P.J., Copeland R.A. Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry (N.Y.) (2008) 47 8465.
31. Vauquelin G., Van Liefde I. Slow antagonist dissociation and long-lasting in vivo receptor protection. Trends Pharmacol. Sci. (2006) 27 356-359.
32. Ojima M., Inada Y., Shibouta Y. et al. Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor. Eur. J. Pharmacol. (1997) 319 137-146.
33. Morsing P., Adler G., Brandt-Eliasson U. et al. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. Hypertension (1999) 33 1406-1413.
34. Fierens F., Vanderheyden P.M., De Backer J.P., Vauquelin G. Binding of the antagonist [3H]candesartan to angiotensin II AT1 receptor-transfected [correction of tranfected] Chinese hamster ovary cells. Eur. J. Pharmacol. (1999) 367 413-422.
35. Le M.T., Pugsley M.K., Vauquelin G., Van Liefde I. Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor. Br. J. Pharmacol. (2007) 151 952-962.
36. Anderson G.P. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator. Life Sci. (1993) 52 2145-2160.
37. Anderson G.P., Linden A., Rabe K.F. Why are long-acting beta-adrenoceptor agonists long-acting? Eur. Respir. J. (1994) 7 569-578.
38. Szczuka A., Wennerberg M., Packeu A., Vauquelin G. Molecular mechanisms for the persistent bronchodilatory effect of the beta2-adrenoceptor agonist salmeterol. Br. J. Pharmacol. (2009) 158 183-194.
39. Wennerberg M., Balendran A., Clapham J.C., Vauquelin G. Unravelling the complex dissociation of [(3)H]-rimonabant from plated CB(1) cannabinoid receptor-expressing cells. Fundam. Clin. Pharmacol. (2010) 24 181-187.
40. Felder C.C., Joyce K.E., Briley E.M. et al. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol. (1995) 48 443-450.
41. Vauquelin G., Szczuka A. Kinetic versus allosteric mechanisms to explain insurmountable antagonism and delayed ligand dissociation. Neurochem. Int. (2007) 51 254-260.
42. Goldstein B., Posner R.G., Torney D.C., Erickson J., Holowka D., Baird B. Competition between solution and cell surface receptors for ligand. Dissociation of hapten bound to surface antibody in the presence of solution antibody. Biophys. J. (1989) 56 955-966.
43. Simard J.R., Zunszain P.A., Hamilton J.A., Curry S. Location of high and low affinity fatty acid binding sites on human serum albumin revealed by NMR drug-competition analysis. J. Mol. Biol. (2006) 361 336-351.
44. Lindstrom E., von Mentzer B., Pahlman I. et al. Neurokinin 1 receptor antagonists: correlation between in vitro receptor interaction and in vivo efficacy. J. Pharmacol. Exp. Ther. (2007) 322 1286-1293.